The transfer of stromal-cell-derived miR-320a inhibits the tumour progression of HCC cells by binding to its direct target PBX3. These results qualify the method of miRNA transfer as a potential treatment option for HCC progression [99]. The gene discussed is PBX3; the disease is hepatocellular carcinoma.